Corticosteroids are immunomodulatory hormones that are known to inhibit the proliferation of the inflammatory response. 8, 9 Their use in patients with neurocysticercosis followed clinical observations of side effects associated with the initiation of anthelmintic therapies. 10 As inflammation is deemed responsible for the majority of the clinical manifestations of the disease, it is not surprising that they are of common use in clinical practice, and there have been several randomized trials assessing their effectiveness with inconsistent results. 4 Despite this, a systematic evaluation of the current evidence has not been performed. We aimed to evaluate and synthesize the evidence on the use of corticosteroids for the treatment of children and adults with neurocysticercosis for the resolution of seizure recurrences and lesion disappearance on computed tomography (CT) or magnetic resonance imaging (MRI). Abstracts from congresses of infectious and neurologic disease societies were sought. Clinical researchers, local experts and organizations were contacted when necessary and references were crosschecked.
Methods

Search strategy and selection criteria
We included randomized and quasi-randomized controlled trials that evaluated both children and adults with the diagnosis of neurocysticercosis by clinical and imaging confirmation. Any type of corticosteroid given by enteral or parenteral route was considered as an intervention arm.
Comparisons to evaluate were: (1) corticosteroid versus placebo/no drug; (2) corticosteroid plus albendazole versus placebo/no drug; (3) corticosteroid versus albendazole; (4) corticosteroid plus albendazole versus albendazole; (5) corticosteroid plus albendazole versus corticosteroid.
Our primary outcomes included the rate of seizure recurrence, defined as one or more convulsions after the initial episode and within 12 months of the first seizure, and the rate of lesion persistence on the imaging studies, by MRI or CT scan. Radiologic resolution was defined when the lesion completely disappeared, with none or minimal residual scar, calcification, or perilesional edema.
Secondary outcomes included adverse events related to the corticosteroid therapy, i.e., headaches, abdominal pain, rash, and other infections. Although death was considered unlikely to happen, any such event was sought and analyzed.
Data extraction
Two authors (CC and YR) independently assessed the eligibility of studies, and based on the inclusion criteria, extracted data and assessed the risk of bias of the included studies on a pre-piloted data extraction form. Discrepancies were resolved with the third and fourth authors (GP and JV). Data to extract included the setting, patient characteristics, year of study, definitions, and results based on the primary and secondary outcomes.
Quality assessment
Two authors (CC and YR) independently evaluated the risk of bias for each included study. Any discrepancies were settled with the third and fourth authors (GP and JV) by informal consensus.
The Cochrane Collaboration's tool 11 for assessing risk of bias was used, and it includes an assessment of: (1) an adequate sequence generation, (2) allocation concealment, (3) blinding (masking) of participants, personnel, and outcome assessors, (4) if incomplete outcome data was possible, (5) selective outcome reporting, and (6) if other sources of bias were considered. We determined the risk of bias for each component using 'yes', 'no', or 'unclear', indicating a low, high, or unclear/unknown risk of bias, respectively.
Statistical analysis
Review Manager 5.1 software was used for the data synthesis and analysis. Combined risk ratios (RR) for dichotomous outcomes were used with the Mantel-Haenszel method and a random effects model approach. We expected a low rate of adverse events and decided to use the Peto odds ratio (OR) for the adverse event outcome.
Considering unit of analysis issues in trials with more than two intervention arms of study, the number of participants was evenly divided and analyzed as individual pair-wise comparisons to ensure that participants in the placebo group were not counted more than once. Whenever possible and if necessary, data on all participants were extracted from studies that reported sufficient information for an intention-to-treat analysis. We tried to contact authors of individual studies if details of trial design or descriptive statistics for outcomes were not present in the study. If the authors did not respond within 3-6 weeks, we conducted the review based only on the available information.
We evaluated heterogeneity using forest plots to detect overlapping confidence intervals, and applied the Chi-square test, with a p-value of 0.10 used to indicate statistical significance. We also implemented the I 2 statistic, with a value of 50% used to denote moderate levels of heterogeneity. Publication bias was visually assessed with funnel plots on different comparisons looking for asymmetry. We also tried to contact experts and authors of identified studies and ask whether they had other publications or were aware of any other unpublished studies. Public trial registries were also searched for ongoing or incomplete studies.
Overall evidence was assessed using the GRADE approach, and summary of findings tables were constructed using GRADEpro software. 12, 13 Sensitivity analyses were devised based on: (1) the quality of individual trials (blinding of outcome assessors, blinding of participants, and levels of attrition bias), (2) age of participants (children vs. adults), and (3) the type of lesion in the imaging study as 'viable', 'non-viable', or mixed. 7 
Results
Results of the search
The preliminary searches identified 63 potential citations. We read the titles and abstracts of these studies. Thirteen articles with 1373 participants were determined to be eligible ( Figure 1 ). All of them were included in the final quantitative and qualitative analysis and are described in Table 1 . The excluded studies and reasons for their exclusion are given in the Supplementary Material (supplement 2).
Risk of bias in included studies
Regarding allocation (selection) bias, only five studies 10, [14] [15] [16] [17] had a good description of how the random sequence list was generated. Of these, only one 15 did not describe a proper allocation concealment process (i.e., sealed opaque envelopes or a statistician not involved in the process of allocation). Four trials 10, 14, 15, 17 adequately blinded personnel and participants of the study by using and describing placebos, as well as the blinding of the outcome assessors.
Attrition bias was deemed unlikely among most of the studies. Only in three studies [17] [18] [19] were dropouts considered sufficient to be classified as unclear risk, and in two trials 14, 16 there were concerns about dropouts and their adequate analyses, hence a high risk of bias was considered and sensitivity analyses were performed as described below. All studies had a low risk of reporting (selective reporting) bias. Not relevant to our study (4) Other systematic reviews (5) Narrative reviews (22) Other treatments (8) Case series (2) Case reports (2) Study in animals (1) Figure 1 . Study flowchart. On visual inspection of the funnel plot (Supplementary Material, supplement 4), publication bias was considered highly possible.
Effects of interventions 3.3.1. Corticosteroids versus no drug or placebo
Five studies comparing corticosteroid alone to no drug/placebo were included. 17, [20] [21] [22] [23] The rate of seizure recurrence at 6-12 months of follow-up was reduced in the corticosteroid group (RR 0.46, 95% CI 0.27-0.77; 426 participants, five trials). Also, corticosteroids reduced the rate of lesion persistence on MRI or CT scan at 6-12 months of follow-up (RR 0.63, 95% CI 0.43-0.92; 417 participants, five trials); see Figure 2 .
Corticosteroids plus albendazole versus no drug or placebo
Three studies 10, 16, 24 evaluated this combination compared to no drug/placebo. There were no statistically significant effects of this combination for reducing the rate of seizure recurrence (RR 0.98, 95% CI 0.53-1.82; 504 participants, three trials) or lesion persistence in imaging studies (RR 0.88, 95% CI 0.69-1.12; 500 participants, three trials) (Figure 3 ).
Corticosteroids versus albendazole
Only one study 25 (Figure 4 ).
Sensitivity analyses
We first performed a sensitivity analysis based on the risk of bias of individual studies.
On the comparison of corticosteroids versus placebo/no drug (with five trials), only the study by Singla et al. 17 had a low risk of bias, with a result of no difference between arms of the study for both the outcome of seizure recurrence (RR 0.86, 95% CI 0.49-1.51) and lesion persistence in imaging studies (RR 0.89 95% CI 0.64-1.22); the final result with only the four high risk of bias studies remained significant. On the comparison of corticosteroids plus albendazole versus placebo/no drug, the exclusion of high risk of bias studies left the analysis with only one good quality study, 10 for which results showed no effect on the rate of seizure recurrence (RR included both viable and non-viable lesions and the other nine studies included only non-viable lesions. No change in the final effect was observed in all comparisons and in all outcomes evaluated. Further sensitivity analyses were not feasible (i.e., number and/or location of the lesions) because of a lack of information from individual studies.
Adverse events
This outcome was difficult to ascertain, as there were different definitions and probable underreporting among different trials. On qualitative analysis, the most common reported adverse reactions were skin rashes, erythema multiforme minor, headache, and abdominal pain or discomfort. The use of corticosteroids alone versus placebo or no drug did not increase adverse events (Peto OR 0.46 95% CI 0.17-1.25; 355 participants, four studies). 17, 20, 22, 23 There were no studies evaluating adverse events in the comparisons of corticosteroids versus albendazole, or corticosteroids plus albendazole versus albendazole.
However, when compared to no therapy or placebo the combination of corticosteroids plus albendazole increased the risk of abdominal pain and abdominal discomfort (Peto OR 8.73, 95% CI 2.09-36.5; 116 participants, one trial). 10 Also, this combination increased the risk of presenting abdominal pain or headache when compared to corticosteroids alone (Peto OR 4.90, 95% CI 1.84-13.06; 191 participants, two studies).
14,18
The death rate was similar among study groups in those trials that reported this outcome.
Discussion
Inflammation is considered responsible for the clinical manifestations in patients with cerebral cysticercosis. 4 Corticosteroids have been indicated as a first-line therapy by clinicians who justify their use hoping to control the inflammatory response that occurs during the natural disappearance of the lesions, or as a result of anthelmintic therapy. Notwithstanding this being a common textbook approach 26 and a current recommendation in clinical practice guidelines, 27 there is no unique regimen or standard of use.
In this systematic review corticosteroids used alone reduced the rate of seizure recurrence and the persistence of lesions in imaging studies in a range of 6-12 months of follow-up. However, with the exception of one study, 17 all trials making this comparison were considered as having a high risk of bias, hence the overall body of evidence was weighted as very low quality using the GRADE approach (Table 2) . It is important to note the critical possibility of publication bias, as it was evident from visual inspection in the funnel plot (Supplementary Material, supplement 4). With the current evidence analyzed, we cannot be certain whether corticosteroids used alone or in combination with an anthelmintic could provide more desirable than undesirable effects.
Combining corticosteroids and albendazole is an option that could make sense in clinical practice. However, our results did not show an effect on reducing the rate of seizure recurrence or lesion persistence in imaging studies. Within the three studies that evaluated these outcomes, only one trial with a low risk of bias 10 showed a benefit of using this combination. The other two presented a high risk of bias and wide confidence intervals (Table 3) . Furthermore adverse events (abdominal pain or discomfort) were more frequently reported.
We evaluated other comparisons, but none of them showed a statistical or clinical significance, and most of the studies included had an increased risk of bias.
The comparisons of corticosteroids versus albendazole and corticosteroids plus albendazole versus albendazole alone were assessed in the three-arm study of Singhi et al., 25 showing no difference between the study arms and wide confidence intervals to reach a conclusion. We found five studies evaluating corticosteroids plus albendazole versus corticosteroids alone, and although there was a tendency for this combination towards reducing the rate of lesion persistence in imaging studies, it did not reach statistical significance, the overall quality of the evidence was deemed low to very low (Table 4) , and adverse events (headache and abdominal pain) were significantly more frequent in the intervention group.
This systematic review might have some limitations. Overall the quality of the evidence of included studies assessed with the GRADE methodology was considered from very low to moderate. Although all 13 studies are classified as randomized, only a few adequately described sequence generation or allocation concealment.
Patients participating in the included studies were from lowand middle-income countries (Ecuador, India, and Peru) and were recruited mostly from tertiary care centers; no studies from highincome countries were found, thus the applicability of the evidence in these settings remains questionable. Rash or abdominal pain were considered for this comparison CI, confidence interval; CT, computed tomography; MRI, magnetic resonance imaging; OR, odds ratio (Peto); RR, risk ratio. a The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). b GRADE Working Group grades of evidence: high quality: further research is very unlikely to change our confidence in the estimate of effect; moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality: we are very uncertain about the estimate. c Except for the study by Singla et al., 17 random sequence generation, random allocation concealment, and blinding not described or poorly performed; poor outcome Regarding age groups, only three trials included exclusively pediatric participants. The sensitivity analyses did not demonstrate a different effect between children and adults. Whether corticosteroids or different combinations have a different effect on children and adults is difficult to ascertain and more studies are necessary to elucidate this issue.
Because of a lack of information from individual studies, we could not perform sensitivity analyses regarding the number, type, and/or location of the lesions; we are aware that these could be important prognostic factors to consider in future studies.
Even when every effort was made to retrieve all relevant trials without restrictions, the possibility of publication bias was deemed high on visual inspection in the funnel plot (Supplementary Material, supplement 4). This observation is of concern, as there is a high possibility that those trials with negative results are not being published, and their inclusion could change the direction of our findings on several comparisons in this systematic review.
As with any systematic review, the process of data extraction, assessments of the risk of bias, and data entry are subjective and might be prone to errors.
To our knowledge this is the first systematic review addressing the comparisons between corticosteroids versus placebo or no drugs or a combination of therapies that include at least a corticosteroid in one arm.
Diverse recommendations from different sources might be confusing for the clinician. Some clinical practice guidelines and expert consensuses state that corticosteroids could have some benefit in specific situations (e.g., periventricular cysts and large cysts in the Sylvian fissure), 27 meanwhile other information resources for clinicians still consider corticosteroids as a first-line therapy for all types of presentations; 26 none of these recommendations, however, are based on solid evidence. A recent narrative review 4 addressed the use of corticosteroids in patients with neurocysticercosis, but there was no formal description of the search strategy, data extraction, assessment of risk of bias, or a formal compilation of the results in a meta-analysis.
Regarding the use of anthelmintics, a recent Cochrane systematic review by Abba et al. 7 evaluated the use of albendazole for patients with neurocysticercosis. They also studied the combinations included in our review and their conclusions are mostly in agreement with our results. Although the authors emphasize using sub-group analyses based on viable or non-viable lesions, in our sensitivity analysis we did not find this dichotomization clinically different or useful. The authors concluded that albendazole might reduce the rate of seizure recurrence and lesion persistence and assert that the evidence is equivocal and more studies are needed. Future studies should include an adequate sample size, random sequence generation, allocation concealment, and blind measurement of clinical endpoints. They should address the same clinical outcomes of seizure recurrence and lesion persistence in imaging studies, and even add the acute effects (mass effect and seizures in the first hours after treatment). A factorial design might achieve these goals and ideally the arms of the study would be: (1) corticosteroids alone, (2) corticosteroids plus albendazole, (3) albendazole, and (4) placebo. Stratification of the study should be considered regarding age and type, location, size, and number of cysts in imaging studies.
In conclusion, due to a high risk of methodological bias as well as publication bias we cannot be certain whether corticosteroids alone or in combination with anthelmintics could reduce the rate of seizure recurrence or lesion disappearance in imaging studies. Although our results suggest corticosteroids can reduce the rate of seizure recurrence and speed up resolution of lesions, there remains uncertainty on the effect estimate and further research is very likely to change our confidence in these results. If clinicians decide to use corticosteroids as a first-line therapy, they should consider carefully if the possible benefits outweigh the risks and consider the costs on an individual patient basis.
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